What's Happening?
Corcept Therapeutics presented data from its MOMENTUM trial at the American College of Cardiology Annual Scientific Session, revealing that 27.3% of patients with resistant hypertension also have hypercortisolism. The trial, which is the largest of its kind
in the U.S., screened 1,086 patients across 50 sites. The findings suggest that hypercortisolism is more prevalent in patients with resistant hypertension than previously thought. This condition, also known as Cushing’s syndrome, can lead to severe health issues if untreated. The trial's results highlight the importance of screening for hypercortisolism in patients with difficult-to-control hypertension and diabetes, potentially leading to more personalized and effective treatment strategies.
Why It's Important?
The MOMENTUM trial's findings are crucial as they provide new insights into the prevalence of hypercortisolism among patients with resistant hypertension, a condition that significantly increases the risk of cardiovascular events. By identifying hypercortisolism in a substantial portion of these patients, the study underscores the need for routine screening, which could lead to better management and treatment outcomes. This research could influence clinical practices and guidelines, encouraging healthcare providers to consider hypercortisolism as a contributing factor in resistant hypertension cases. The trial's results may also drive further research into targeted therapies, improving patient care and reducing the risk of severe complications.
